Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (87) clinical trials

M7824 in Consensus Molecular Subtype 4 Treatment-Refractory Metastatic Colorectal Cancer

Study Drug Administration: Each cycle is about 4 weeks. If you are found to be eligible to take part in this study, you will receive M7824 by vein for about 1 hour on Days 1 and 15 of each cycle. Length of Treatment: You may continue taking the study drug ...

Phase

Pembrolizumab Combination Chemotherapy and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab when combined with radiotherapy plus carboplatin and paclitaxel in locally advanced gastroesophageal junction (GEJ)/cardia adenocarcinoma. (Phase Ib) II. To determine the safety and tolerability of pembrolizumab when combined with oxaliplatin, leucovorin calcium, and fluorouracil (mFOLFOX6) (without radiation) in locally ...

Phase

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Treatment of patients with advance solid tumor is great unsolved challenge to the physicians. Efficacy of conventional treatment, such as surgery, radiotherapy and chemotherapy is limited. AS novel therapy, immunotherapy shows great prospects. Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism,and intracellular granzyme B expression may ...

Phase

PEN-866 in Patients With Advanced Solid Malignancies

Phase 1 will employ an adaptive model guided with overdose control principle to make dose recommendations and estimate the maximum tolerated dose (MTD). Phase 2a begins once all patients treated in Phase 1 have been assessed for safety and the Safety Review Committee (SRC) has reviewed all safety data and ...

Phase

Study of HBI-8000 With Nivolumab in Melanoma Renal Cell Carcinoma and Non-Small Cell Lung Cancer

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC). The primary objective of this study is: -To evaluate the safety and tolerability of HBI-8000 when ...

Phase

Study of Taladegib in Combination With Weekly Paclitaxel Carboplatin and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group (Phase 1B or Phase 2) based on when you join this study. If you are in Phase 1B, the dose of Taladegib that you will receive is ...

Phase

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

PRIMARY OBJECTIVES: I. Determine the recommended phase II dose for the combination of TAS-102 and nanoliposomal irinotecan (nanoliposomal [nal]-IRI). (Phase I) II. Evaluate the activity of the combination of TAS102 and nal-IRI in previously treated patients with metastatic colorectal cancer and pancreatic cancer. (Phase II) SECONDARY OBJECTIVES: I. Define the ...

Phase

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

This study is an open-label Phase 1 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. Single Agent INCB001158: Patients with advanced/metastatic solid tumors will be enrolled into escalating monotherapy dose cohorts to determine the Recommended Phase 2 Dose ...

Phase

Phase 1/2A Study of TRC253 an Androgen Receptor Antagonist in Metastatic Castration-resistant Prostate Cancer Patients

The patient population consists of men 18 years of age with adenocarcinoma of the prostate with metastatic disease. Patients who have not undergone orchiectomy must have serum testosterone levels <50 ng/dL determined within 4 weeks prior to start of study drug, and, if applicable, must have discontinued treatment with first ...

Phase

The Study to Evaluate JS001 in Patients With Advanced GC ESCC NPC HNSCC

Overall Design: This is a multicenter, open-label, phase Ib/II clinical study of recombinant humanized anti-programmed death receptor 1 (PD-1) monoclonal antibody for injection (JS001) in patients with gastric adenocarcinoma (GC), esophageal squamous cell carcinoma (ESCC), nasopharyngeal carcinoma (NPC), or head and neck squamous cell carcinoma (HNSCC). On the basis of ...

Phase